Zarontin (ETHOSUXIMIDE)
Zarontin (ETHOSUXIMIDE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Zarontin; Generic name: ETHOSUXIMIDE; Drug class: Anti-epileptic Agent [EPC].
| Brand name | Zarontin |
|---|---|
| Generic name | ETHOSUXIMIDE |
| Drug class | Anti-epileptic Agent [EPC] |
| Manufacturer | Parke-Davis Div of Pfizer Inc |
| Used for | INDICATIONS AND USAGE Zarontin is indicated for the control of absence (petit mal) epilepsy. |
| Dosage | DOSAGE AND ADMINISTRATION Zarontin is administered by the oral route. The initial dose for patients 3 to 6 years of age is one capsule (250 mg) per day; for patients 6 years of age and older, 2 capsules (500 mg) per day. The dose thereafter must be individualized according to the patient's response. Dosage should be increased by small increments. One useful method is to increase the daily dose by 250 mg every four to seven days until control is achieved with minimal side effects. Dosages exceedi |
| Warnings | WARNINGS Blood Dyscrasias: Blood dyscrasias, including some with fatal outcome, have been reported to be associated with the use of ethosuximide; therefore, periodic blood counts should be performed. Should signs and/or symptoms of infection (e.g., sore throat, fever) develop, blood counts should be considered at that point. Drug-Induced Immune Thrombocytopenia: Drug-induced immune thrombocytopenia (DITP) has been reported with ethosuximide. In the reported cases, the onset of symptoms occurred |
| Active ingredient(s) | ETHOSUXIMIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e008f33-70a1-4bc6-b3a0-d45214418ab6 |